NovaBridge Biosciences (NBP)
NASDAQ: NBP · Real-Time Price · USD
2.390
-0.040 (-1.65%)
At close: Apr 28, 2026, 4:00 PM EDT
2.580
+0.190 (7.95%)
After-hours: Apr 28, 2026, 7:59 PM EDT
NovaBridge Biosciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2017 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2017 |
| Revenue | - | - | 0.63 | -1.55 | 13.86 | Upgrade
|
| Revenue Growth (YoY) | - | - | - | - | -94.14% | Upgrade
|
| Cost of Revenue | - | - | - | - | 7.31 | Upgrade
|
| Gross Profit | - | - | 0.63 | -1.55 | 6.55 | Upgrade
|
| Selling, General & Admin | 31.36 | 29.66 | 28.16 | 28.98 | 141.67 | Upgrade
|
| Research & Development | 62.91 | 21.77 | 21.45 | 22.55 | 190.94 | Upgrade
|
| Operating Expenses | 94.27 | 51.43 | 49.61 | 51.53 | 332.6 | Upgrade
|
| Operating Income | -94.27 | -51.43 | -48.98 | -53.08 | -326.06 | Upgrade
|
| Interest & Investment Income | 7.61 | 7.49 | 9.29 | 4.95 | 3.36 | Upgrade
|
| Earnings From Equity Investments | - | -1.04 | -11.4 | -64.71 | -57.91 | Upgrade
|
| Currency Exchange Gain (Loss) | -0 | -5.57 | -8.04 | -33.75 | 3.99 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.07 | 14.49 | -0.05 | 5.48 | 4.32 | Upgrade
|
| EBT Excluding Unusual Items | -86.59 | -36.06 | -59.18 | -141.1 | -372.3 | Upgrade
|
| Impairment of Goodwill | - | - | -23.04 | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | -1.75 | - | - | - | 4.78 | Upgrade
|
| Asset Writedown | - | -1.25 | - | - | - | Upgrade
|
| Other Unusual Items | - | -12.39 | - | - | - | Upgrade
|
| Pretax Income | -88.34 | -49.7 | -82.22 | -141.1 | -367.52 | Upgrade
|
| Income Tax Expense | - | - | - | 0.1 | -0.5 | Upgrade
|
| Earnings From Continuing Operations | -88.34 | -49.7 | -82.22 | -141.2 | -367.02 | Upgrade
|
| Earnings From Discontinued Operations | - | 27.47 | -125.51 | -229.85 | - | Upgrade
|
| Net Income | -88.34 | -22.23 | -207.73 | -371.05 | -367.02 | Upgrade
|
| Net Income to Common | -88.34 | -22.23 | -207.73 | -371.05 | -367.02 | Upgrade
|
| Shares Outstanding (Basic) | 96 | 81 | 83 | 83 | 76 | Upgrade
|
| Shares Outstanding (Diluted) | 96 | 81 | 83 | 83 | 76 | Upgrade
|
| Shares Change (YoY) | 17.96% | -2.45% | 0.86% | 8.63% | 11.11% | Upgrade
|
| EPS (Basic) | -0.92 | -0.27 | -2.50 | -4.50 | -4.83 | Upgrade
|
| EPS (Diluted) | -0.92 | -0.27 | -2.50 | -4.50 | -4.83 | Upgrade
|
| Free Cash Flow | -20.6 | -106.68 | -146.66 | -92.32 | -157.89 | Upgrade
|
| Free Cash Flow Per Share | -0.21 | -1.31 | -1.76 | -1.12 | -2.08 | Upgrade
|
| Gross Margin | - | - | 100.00% | - | 47.25% | Upgrade
|
| Operating Margin | - | - | -7749.37% | - | -2353.06% | Upgrade
|
| Profit Margin | - | - | -32868.51% | - | -2648.70% | Upgrade
|
| Free Cash Flow Margin | - | - | -23206.33% | - | -1139.46% | Upgrade
|
| EBITDA | -94.2 | -51.17 | -48.5 | -52.87 | -323.89 | Upgrade
|
| D&A For EBITDA | 0.07 | 0.26 | 0.48 | 0.21 | 2.17 | Upgrade
|
| EBIT | -94.27 | -51.43 | -48.98 | -53.08 | -326.06 | Upgrade
|
| Revenue as Reported | - | - | 0.63 | -1.55 | 13.86 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.